Cargando…

Bimatoprost versus Clobetasol Propionate in Scalp Alopecia Areata: A Prospective Non-Randomized Open-Label Clinical Trial

BACKGROUND: Alopecia areata (AA) is one of the most common forms of alopecia presenting to the dermatology out patient department (OPD) worldwide as well as in Nepal. It is mostly diagnosed clinically. Treatment depends on the extent, location, and severity of the condition. Various treatment option...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhusal, Mohan, Bhattarai, Sabina, Thapa, Binita, Shrestha, Prashanna R., Sagar, G. C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115310/
https://www.ncbi.nlm.nih.gov/pubmed/37089845
http://dx.doi.org/10.4103/idoj.idoj_299_22
_version_ 1785028183478763520
author Bhusal, Mohan
Bhattarai, Sabina
Thapa, Binita
Shrestha, Prashanna R.
Sagar, G. C
author_facet Bhusal, Mohan
Bhattarai, Sabina
Thapa, Binita
Shrestha, Prashanna R.
Sagar, G. C
author_sort Bhusal, Mohan
collection PubMed
description BACKGROUND: Alopecia areata (AA) is one of the most common forms of alopecia presenting to the dermatology out patient department (OPD) worldwide as well as in Nepal. It is mostly diagnosed clinically. Treatment depends on the extent, location, and severity of the condition. Various treatment options available are topical, intralesional, and oral medications. Bimatoprost is a relatively newer treatment modality in AA. AIM AND OBJECTIVE: To compare the efficacy and safety of topical bimatoprost 0.01% solution versus clobetasol propionate 0.05% cream in scalp AA. MATERIALS AND METHODS: A total of 50 patients attending the dermatology OPD of a tertiary hospital between March 2018 and February 2019 were included in this prospective non-randomized open-label clinical trial. Patients were divided into two groups i.e., Group A- topical bimatoprost solution 0.01% and Group B- topical clobetasol propionate cream 0.05%, and followed up at weeks 4, 8, and 12. The improvement was analyzed subjectively by hair regrowth and objectively by Severity of Alopecia Tool (SALT) score. Side effects, nature of terminal hair and onset of initial response were also recorded. RESULTS: Out of 50 patients, 27 were males and 23 were females with a mean age of 28.5 ± 9.34 years and mean duration of disease of 18.67 ± 46.1 weeks. Hair regrowth rate and reduction in SALT score from baseline were seen more in clobetasol group compared to bimatoprost (p = 0.282 and P = 0.246, respectively). Side effects were seen more in the clobetasol group compared to bimatoprost group (p = 0.002). Onset of cosmetically acceptable hair regrowth was seen earlier in the bimatoprost group (p = 0.017) and also the nature of regrown hairs was more pigmented in bimatoprost group (p = 0.024). CONCLUSIONS: There is no significant difference in hair regrowth between clobetasol and bimatoprost in the treatment of AA on scalp at the end of 12 weeks, although bimatoprost has an advantage of lesser side effects, more rapid response and growth of more pigmented hairs.
format Online
Article
Text
id pubmed-10115310
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-101153102023-04-20 Bimatoprost versus Clobetasol Propionate in Scalp Alopecia Areata: A Prospective Non-Randomized Open-Label Clinical Trial Bhusal, Mohan Bhattarai, Sabina Thapa, Binita Shrestha, Prashanna R. Sagar, G. C Indian Dermatol Online J Brief Report BACKGROUND: Alopecia areata (AA) is one of the most common forms of alopecia presenting to the dermatology out patient department (OPD) worldwide as well as in Nepal. It is mostly diagnosed clinically. Treatment depends on the extent, location, and severity of the condition. Various treatment options available are topical, intralesional, and oral medications. Bimatoprost is a relatively newer treatment modality in AA. AIM AND OBJECTIVE: To compare the efficacy and safety of topical bimatoprost 0.01% solution versus clobetasol propionate 0.05% cream in scalp AA. MATERIALS AND METHODS: A total of 50 patients attending the dermatology OPD of a tertiary hospital between March 2018 and February 2019 were included in this prospective non-randomized open-label clinical trial. Patients were divided into two groups i.e., Group A- topical bimatoprost solution 0.01% and Group B- topical clobetasol propionate cream 0.05%, and followed up at weeks 4, 8, and 12. The improvement was analyzed subjectively by hair regrowth and objectively by Severity of Alopecia Tool (SALT) score. Side effects, nature of terminal hair and onset of initial response were also recorded. RESULTS: Out of 50 patients, 27 were males and 23 were females with a mean age of 28.5 ± 9.34 years and mean duration of disease of 18.67 ± 46.1 weeks. Hair regrowth rate and reduction in SALT score from baseline were seen more in clobetasol group compared to bimatoprost (p = 0.282 and P = 0.246, respectively). Side effects were seen more in the clobetasol group compared to bimatoprost group (p = 0.002). Onset of cosmetically acceptable hair regrowth was seen earlier in the bimatoprost group (p = 0.017) and also the nature of regrown hairs was more pigmented in bimatoprost group (p = 0.024). CONCLUSIONS: There is no significant difference in hair regrowth between clobetasol and bimatoprost in the treatment of AA on scalp at the end of 12 weeks, although bimatoprost has an advantage of lesser side effects, more rapid response and growth of more pigmented hairs. Wolters Kluwer - Medknow 2023-03-03 /pmc/articles/PMC10115310/ /pubmed/37089845 http://dx.doi.org/10.4103/idoj.idoj_299_22 Text en Copyright: © 2023 Indian Dermatology Online Journal https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Brief Report
Bhusal, Mohan
Bhattarai, Sabina
Thapa, Binita
Shrestha, Prashanna R.
Sagar, G. C
Bimatoprost versus Clobetasol Propionate in Scalp Alopecia Areata: A Prospective Non-Randomized Open-Label Clinical Trial
title Bimatoprost versus Clobetasol Propionate in Scalp Alopecia Areata: A Prospective Non-Randomized Open-Label Clinical Trial
title_full Bimatoprost versus Clobetasol Propionate in Scalp Alopecia Areata: A Prospective Non-Randomized Open-Label Clinical Trial
title_fullStr Bimatoprost versus Clobetasol Propionate in Scalp Alopecia Areata: A Prospective Non-Randomized Open-Label Clinical Trial
title_full_unstemmed Bimatoprost versus Clobetasol Propionate in Scalp Alopecia Areata: A Prospective Non-Randomized Open-Label Clinical Trial
title_short Bimatoprost versus Clobetasol Propionate in Scalp Alopecia Areata: A Prospective Non-Randomized Open-Label Clinical Trial
title_sort bimatoprost versus clobetasol propionate in scalp alopecia areata: a prospective non-randomized open-label clinical trial
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115310/
https://www.ncbi.nlm.nih.gov/pubmed/37089845
http://dx.doi.org/10.4103/idoj.idoj_299_22
work_keys_str_mv AT bhusalmohan bimatoprostversusclobetasolpropionateinscalpalopeciaareataaprospectivenonrandomizedopenlabelclinicaltrial
AT bhattaraisabina bimatoprostversusclobetasolpropionateinscalpalopeciaareataaprospectivenonrandomizedopenlabelclinicaltrial
AT thapabinita bimatoprostversusclobetasolpropionateinscalpalopeciaareataaprospectivenonrandomizedopenlabelclinicaltrial
AT shresthaprashannar bimatoprostversusclobetasolpropionateinscalpalopeciaareataaprospectivenonrandomizedopenlabelclinicaltrial
AT sagargc bimatoprostversusclobetasolpropionateinscalpalopeciaareataaprospectivenonrandomizedopenlabelclinicaltrial